113 results for "Spike RBD" in Products
Spike RBD Products
The coronavirus Spike protein receptor binding domain (RBD) resides within the S1 subunit and is responsible for binding to host cell receptors and initiating viral infection. Past coronaviruses SARS and MERS along with the global pandemic caused by SARS-CoV-2 have sparked great interest and scientific discovery leading to new vaccines and drug dev...
HEK293 Expressed, High ACE-2 Binding
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
HEK293 Expressed, High ACE-2 Binding
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Tn5 Insect Cell Expressed, High ACE-2 Binding Analyzed by SEC-MALS
| Reactivity: | SARS-CoV-2 |
| Source: | T. ni (baculovirus) |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
N501Y Mutation found in Alpha, Beta, and Gamma Variants
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Mammalian CHO Cell Expressed, High ACE-2 Binding
| Reactivity: | SARS-CoV-2 |
| Source: | CHO |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Beta Variant (South Africa), K417N, E484K, N501Y
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Sf21 Expressed, High ACE-2 Binding
| Reactivity: | SARS-CoV-2 |
| Source: | Sf 21 (baculovirus) |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
HEK293 Expressed
| Reactivity: | SARS-CoV |
| Source: | HEK293 |
| Accession #: | P59594.1 |
| Applications: | Bioactivity |
| Reactivity: | MERS-CoV |
| Source: | CHO |
| Accession #: | YP_007188579.1 |
| Applications: | Bioactivity |
Val367Phe Point Mutation
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Gly476Ser Point Mutation
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Val483Ala Point Mutation
| Reactivity: | SARS-CoV-2 |
| Source: | CHO |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
HEK293 Expressed. Trimerization domain.
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Mouse IgG2a Fc Chimera
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
CHO Expressed. Trimerization Domain
| Reactivity: | SARS-CoV-2 |
| Source: | CHO |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
N501Y Mutation found in UK, South African, and Brazilian Variants
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
Gamma Variant (Brazil) K417T, E484K, N501Y
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
CAL.20C
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Applications: | Bioactivity |
| Reactivity: | SARS-CoV-2 |
| Source: | HEK293 |
| Accession #: | YP_009724390.1 |
| Applications: | Bioactivity |
